The pancreas is a roughly 80 g organ tucked behind the stomach, running horizontally from the duodenum across to the spleen. It has two completely different jobs in the same tissue: the exocrine pancreas pumps digestive enzymes into the small intestine, and the endocrine pancreas (the islets of Langerhans) dumps insulin and glucagon into the bloodstream. You do not feel it working. You feel it when it fails.
At a glance
What it does
The exocrine pancreas is the main source of digestive enzymes. Acinar cells secrete pancreatic amylase (carbs), lipase (fats), and proteases like trypsinogen and chymotrypsinogen (proteins). Duct cells secrete a bicarbonate-rich fluid that neutralizes gastric acid arriving in the duodenum. Without pancreatic enzymes, fat and protein digestion collapses and you end up malnourished despite eating.
The endocrine pancreas is the master glucose regulator. Beta cells in the islets secrete insulin in response to rising blood glucose, amino acids, and GLP-1 — insulin pushes glucose into muscle and fat and switches the liver from glucose production to glucose storage. Alpha cells secrete glucagon in response to falling glucose, which tells the liver to release stored glucose and make new glucose from amino acids. Delta cells secrete somatostatin, which modulates both. The islet is a tight feedback system that keeps blood glucose in a narrow range through meals, fasts, and exercise.
How it works
Beta cells sense glucose through GLUT2 transporters — glucose flows in proportional to its blood concentration, gets phosphorylated by glucokinase (the rate limiter), and drives ATP production. Rising ATP closes ATP-sensitive potassium channels, which depolarizes the membrane, opens voltage-gated calcium channels, and triggers insulin vesicle release. Sulfonylurea drugs hit the same channel directly, which is why they cause insulin release whether or not blood glucose is high.
Alpha cells respond to low glucose, high amino acids, and sympathetic activation. Glucagon binds hepatic receptors and drives glycogenolysis and gluconeogenesis — which is why injectable glucagon is the rescue drug for severe hypoglycemia.
The exocrine acinar cells store their proteases as inactive zymogens to prevent auto-digestion. Activation happens in the duodenum when enterokinase converts trypsinogen to trypsin, which then activates the rest. When this safety system fails — duct obstruction, alcohol damage, gallstones — premature activation inside the pancreas produces acute pancreatitis.
When it goes wrong
Type 1 diabetes is autoimmune destruction of beta cells, usually presenting in childhood or adolescence but with a growing "adult-onset" category (LADA). Without insulin, glucose cannot enter cells, the liver keeps dumping more glucose in, and lipolysis produces ketones. Untreated, this leads to diabetic ketoacidosis and death. Treatment is lifelong exogenous insulin. Pancreas and islet transplants work but require immunosuppression.
Type 2 diabetes is mostly a disease of insulin resistance — peripheral tissues stop responding normally, beta cells initially compensate by hypersecreting, then eventually fail. It has a genetic component, but the overwhelming driver in the modern era is adiposity, sedentary behavior, and poor sleep. GLP-1 agonists like semaglutide and tirzepatide have rewritten the treatment landscape, both by improving glucose and by causing substantial weight loss.
Acute pancreatitis is mostly caused by gallstones obstructing the pancreatic duct and alcohol. Severe cases develop systemic inflammatory response, multi-organ failure, and mortality in the 15-30% range. Chronic pancreatitis — usually from years of heavy alcohol use — produces progressive loss of both exocrine (causing steatorrhea) and endocrine (causing Type 3c diabetes) function.
Pancreatic cancer is one of the deadliest common cancers. Most are ductal adenocarcinoma, usually diagnosed late because the pancreas is deep and symptoms (back pain, weight loss, painless jaundice) appear after the tumor is already locally advanced. Five-year survival remains around 10-12% despite decades of research. Risk factors: smoking, chronic pancreatitis, long-standing diabetes, obesity, family history (BRCA2, Lynch syndrome, familial pancreatic cancer).
Interactions
Alcohol is directly toxic to both exocrine and endocrine pancreas in a dose-dependent way. Smoking roughly doubles pancreatic cancer risk. Chronic hyperglycemia accelerates beta cell exhaustion. Obesity-driven insulin resistance is the main push factor in Type 2 diabetes.
GLP-1 agonists work partly by augmenting insulin secretion in a glucose-dependent manner (so they do not cause hypoglycemia in non-diabetics), partly by slowing gastric emptying, and partly by central appetite suppression. SGLT2 inhibitors dump glucose into urine, which reduces the burden on beta cells over time.
Honest take
The Type 2 diabetes epidemic is not mysterious and it is not inevitable. Most cases are driven by a combination of caloric surplus, poor sleep, and minimal physical activity, and most cases can be pushed into remission by losing 10-15% of body weight — demonstrated multiple times in the DiRECT trial and replicated since. GLP-1 drugs are doing real work here, not by fixing biology from a different angle but by making the weight loss that always mattered finally tractable. Avoiding them out of principle when they would actually help you is ideology, not medicine. Meanwhile, anyone drinking heavily should understand they are trading pancreatic function for a feeling — and the exocrine pancreas has no real redundancy once it is damaged.
Sources
- American Diabetes Association, Standards of Care in Diabetes (annual).
- Lean et al., Lancet (2018) — DiRECT trial on Type 2 diabetes remission via weight loss.
- Banks & Freeman, American Journal of Gastroenterology — practice guidelines in acute pancreatitis.
- Kleeff et al., Nature Reviews Disease Primers — pancreatic cancer review.